Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

This trial is testing whether adding an immunotherapy drug (pembrolizumab) to a chemotherapy combination (gemcitabine, vinorelbine, and liposomal doxorubicin, known as GVD) can help patients with relapsed or treatment-resistant Hodgkin lymphoma (a type of blood cancer) who are being considered for a stem cell transplant. **You may be eligible if...** - You have been diagnosed with classical Hodgkin lymphoma, confirmed by biopsy - Your disease has come back or did not respond to one prior chemotherapy regimen - You are eligible to receive a high-dose stem cell transplant - You achieved a complete response (all cancer gone on scans) after 2 cycles of pembrolizumab + GVD - You are 18 years or older and in good general health (ECOG 0 or 1) **You may NOT be eligible if...** - You have had more than one prior line of treatment - You are not eligible for stem cell transplant - You are pregnant or have active autoimmune disease Talk to your doctor to see if this trial is right for you.